{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-122322","form_type":"8-K","ticker":"ACAD","cik":"0001070494","company_name":"ACADIA PHARMACEUTICALS INC","filed_at":"2024-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:07.577549+00:00","generated_at":"2026-05-30T04:17:56.871741+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Acadia Q3 total revenue $250.4M (+18% YoY); net income $32.8M vs year-ago loss","bullets":["NUPLAZID sales $159.2M (+10% YoY); DAYBUE sales $91.2M (+36% YoY).","Net income $0.20 per share vs ($0.40) loss; nine-month net income $82.7M.","Full-year guidance: NUPLAZID $600-610M, DAYBUE $340-350M, total revenue $940-960M.","Entered agreement to sell Rare Pediatric Disease PRV for $150M; one-third of net to Neuren.","Health Canada approved DAYBUE for Rett syndrome under Priority Review."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-122322","json":"https://secwatch.observer/filing/0000950170-24-122322.json","markdown":"https://secwatch.observer/filing/0000950170-24-122322.md","text":"https://secwatch.observer/filing/0000950170-24-122322.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1070494/000095017024122322/0000950170-24-122322-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1070494/000095017024122322/acad-20241106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T04:17:56.871741+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}